Reporter brief
Open-label pilot study of senolytics for mild cognitive impairment and Alzheimer's disease
What happened
ALSENLITE was an open-label pilot study evaluating the safety and feasibility of dasatinib and quercetin (senolytics) in subjects with mild cognitive impairment or Alzheimer's disease. The abstract reports the study design and objective but does not report results, sample size, or effect sizes.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Other; Human.
Subjects with Mild Cognitive Impairment (MCI) or Alzheimer's disease
- Design
- Other
- Sample
- —
- Journal
- Mayo Clinic
- Published
- Jul 17, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.